Using a blood test to guide treatment after pancreatic cancer surgery
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial is for people who had surgery for pancreatic cancer and are now deciding on maintenance therapy. A special blood test (ctDNA) may help doctors choose the best follow-up treatment to prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with pancreatic ductal adenocarcinoma (a common type of pancreatic cancer)
- The cancer had not spread to distant parts of your body before surgery
- You had complete surgical removal of the cancer (R0 resection) within the last 3 months
- You are in good general health (able to do your daily activities with little or no help)
- You have not received any prior chemotherapy, radiation, or other surgery for pancreatic cancer
- You do not have serious problems with your organs or blood, or other active cancers
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a special blood test (ctDNA) can detect tiny amounts of pancreatic cancer left after surgery. It may help doctors monitor who is at higher risk of cancer coming back, so they can tailor follow-up and treatment timing.
This trial studies whether a blood test (ctDNA, a DNA signal from tumors) can help track how pancreatic cancer responds during planned conversion therapy. It may help doctors spot treatment response earlier and guide next steps.
This trial uses a blood test (called cfDNA) to look for early signs of pancreatic cancer. It compares results from people with pancreatic cancer, precancerous changes, non-cancerous pancreatic conditions, and healthy individuals to improve early detection.
This study uses a personalized blood test to look for tiny pieces of tumor DNA in people with pancreatic cancer. It helps doctors understand how the cancer changes during treatment.
This pilot study checks whether a special blood test (ctDNA) can detect cancer signals and work as well as another sample method during biopsies for liver, bile duct, or pancreatic cancers. It may help doctors choose the best way to confirm the diagnosis from biopsy samples.
This study is testing a new blood test to find pancreatic cancer early. It looks for tiny bits of cancer DNA floating in your blood, which could help catch the disease before symptoms start.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.